Preliminary results from two European trials raise the possibility that combining imatinib mesylate (Gleevec) with pegylated interferon alpha 2b (Peg IFN alpha/PegIntron) or cytabarine (Ara-C) might be effective in Philadelphia chromosome-positive chronic myeloid leukemia (CML) patients who do not have a complete response to imatinib alone.
The Italian Cooperative Study Group on CML reported that 93% of the first 57 early chronic phase patients evaluated in an ongoing phase II trial of imatinib and pegylated interferon had a complete hematolgical response within 12 weeks.
The proportion of these patients having an early cytogenetic response was also encouraging 60% in three months. The CML French Group reported all 30 early chronic phase patients in a study combining imatinib and cytabarine had a complete hematological response in a median time of three weeks. At nine months, 57% had a complete cytogenetic response and 80% had a major cytogenetic response to the combination, which is to be tested in a phase III randomized trial.
תגובות רוצה להצטרף לדיון?
יש להתחבר כדי להגיב.
התחבראין תגובות עדיין. היה הראשון להגיב!